Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

May 06, 2024

The panelists provide their final thoughts, exploring the prospective treatment landscape for patients with CRC.

May 06, 2024

The expert panel continues the discussion with thoughts on gaps in our understanding and application of MRD testing for colorectal cancer and a look to the future, highlighting potential advancements.

April 29, 2024

Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.

April 29, 2024

The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.

April 23, 2024

The panel reviews recent data on MRD testing in colorectal cancer, highlighting the INTERCEPT and COSMOS-CRC-01 studies.

April 23, 2024

Benjamin A. Weinberg, MD, presents the case of a 35-year-old man with oligometastatic disease, and the panel provides insights on treatment decisions.

April 19, 2024

Ashish Saxena, MD, PhD, discusses recent shifts in treatment with the use of targeted and immune therapies in non–small cell lung cancer.

April 18, 2024

Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.

April 17, 2024

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the rationale for evaluating nivolumab plus cisplatin-based chemotherapy in first-line urothelial cancer.

April 15, 2024

Pashtoon Murtaza Kasi, MD, MS, emphasizes key aspects of liquid biopsy and ctDNA testing in the MRD treatment landscape.

April 15, 2024

Pashtoon Murtaza Kasi, MD, MS, reviews data from the BESPOKE CRC study, highlighting overall results and patient-reported outcomes.

April 09, 2024

Focusing on the GALAXY arm in the CIRCULATE-Japan study, experts on colorectal cancer discuss how recent data are informing the evolving treatment landscape.

April 05, 2024

Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.

April 01, 2024

John L. Marshall, MD, presents the case of a 52-year-old woman with mid-rectal carcinoma, and the panel offers its initial impressions.

April 01, 2024

The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.

March 25, 2024

Experts on colorectal cancer discuss practical considerations related to MRD testing, highlighting strategies to navigate potential challenges.

March 25, 2024

Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.

March 18, 2024

Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.

March 18, 2024

Colorectal cancer specialists discuss MRD testing platforms and how to choose among the available testing assays.

March 11, 2024

Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.